ClinicalTrials.gg
RecruitingNCT07594548Updated Nov 19, 2026

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

A Phase 1 interventional study of Biospecimen Collection and Computed Tomography in Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 and Clinical Stage III Gastric Cancer AJCC v8, sponsored by Northwestern University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Northwestern University · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing paclitaxel in Adenocarcinoma Of Esophagus — 1 open to participants now, 3 under way, none of them phase 3. Paclitaxel · Adenocarcinoma Of Esophagus.

Planned enrollment
20th of 23
18 · median 39
Started
2026
the only one that year
Phase 1
2 of 28
1 open now
Registered
28th of 28
by date

Among the 28 studies testing paclitaxel in Adenocarcinoma Of Esophagus, this one is the 20th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 1, and was the 28th registered.

Adenocarcinoma Of Esophagus

353 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

1 of the 28 studies testing paclitaxel in Adenocarcinoma Of Esophagus is open now, in 1 country.

By country, each count listing its studies:

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing paclitaxel in Adenocarcinoma Of Esophagus, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving futibatinib with paclitaxel and ramucirumab may be safe and tolerable in treating patients with locally advanced or unresectable gastric, gastroesophageal junction or esophageal adenocarcinoma.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the safety, tolerability and maximum tolerated dose (MTD) for futibatinib in combination with paclitaxel/ramucirumab in patients with confirmed locally advanced/unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma.

SECONDARY OBJECTIVES:

I. To determine the toxicity profile of futibatinib in combination with paclitaxel/ramucirumab in patients with confirmed locally advanced/unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACE) version (v) 6.

II. To evaluate the preliminary activity (overall response rate [ORR], duration of response [DoR], progression free survival [PFS], overall survival [OS]) of futibatinib in combination with paclitaxel/ramucirumab in patients with confirmed locally advanced/unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma.

EXPANSION PHASE OBJECTIVE:

I. To evaluate the activity (ORR and DoR) of futibatinib in combination with paclitaxel/ramucirumab in patients with confirmed locally advanced/unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma.

OUTLINE: This is a dose-escalation study of futibatinib in combination with fixed-dose paclitaxel and ramucirumab followed by a dose-expansion study.

Patients receive ramucirumab intravenously (IV) over 30-60 minutes on days 1 and 15 of each cycle, paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle, and futibatinib orally (PO) once daily (QD) on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), and optional blood and urine sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years.

03

Conditions studied

  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Locally Advanced Esophageal Adenocarcinoma
  • Locally Advanced Gastric Adenocarcinoma
  • Locally Advanced Gastroesophageal Junction Adenocarcinoma
  • Metastatic Esophageal Adenocarcinoma
  • Metastatic Gastric Adenocarcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Unresectable Esophageal Adenocarcinoma
  • Unresectable Gastric Adenocarcinoma
  • Unresectable Gastroesophageal Junction Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed locally advanced/unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma that is microsatellite stable and negative. (American Joint Committee on Cancer [AJCC] staging criteria; https://pmc.ncbi.nlm.nih.gov/articles/PMC5387145/)

    • Note: Histological or cytological test reports from external laboratories outside of Northwestern University (NU) will also be accepted
  • Patients must have per (RECIST) 1.1

    • Note: Patients must have documented unresectable and/or disease on CT or MRI imaging completed prior to registration. Imaging must have been completed within 90 days prior to registration for participants with measurable disease
  • Patients must not have received more than 1 in the metastatic setting.

    • Note: Patients who have received or adjuvant therapy must have completed therapy a year prior to registration in this study. Exception: patients with neoadjuvant or adjuvant therapy who have progressed within 6 months
  • Patients must be age ≥ 18 years
  • Patients must exhibit an (ECOG) performance status of 0 or 1
  • Leukocytes (white blood cells [WBC]) ≥ 2,000/mcL
  • (ANC) ≥ 1500/mcL
  • (Hgb) ≥ 9 g/dL (transfusions within 1 week of registration are not allowed to meet cutoff)
  • (PLT) ≥ 100,000/mcL (transfusions within 1 week of registration are not allowed to meet cutoff)
  • Total ≤ 1.5 x institutional (ULN)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 3 x institutional ULN (unless liver metastases are present, in which case they must be ≤ 5 x ULN)
  • Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN (unless liver metastases are present, in which case they must be ≤ 5 x ULN)
  • Creatinine ≤ 1.5 x Institutional ULN or meeting (CrCl) criteria below
  • Creatinine clearance per the Cockcroft-Gault formula or 24-hour urine collection) ≥ 45 mL/min
  • Phosphate \< ULN
  • (INR) \< 1.5
  • Patient's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA) within 28 days of registration.

    • Note: Random analysis of urine protein with a normal value is sufficient. If urine dipstick or routine analysis indicated proteinuria ≥ 2+, then a 24-hour urine is to be collected and demonstrate \< 1000 mg of protein in 24 hours to allow participation in the study
  • For patients with a known history of (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration.

    • Please note: this lab is not a requirement for eligibility, however, if it has been completed previously as part of the patient's health care, it should be documented for eligibility
  • Patients with known history of chronic virus (HBV) infection must be on suppressive therapy with an undetectable viral load.

    • Please note: this lab is not a requirement for eligibility, however if it has been completed previously as part of the patient's health care, it should be documented for eligibility
  • Patients with a known history of virus (HCV) infection must have been treated and cured. For patients with a known HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load.

    • Please note: this lab is not a requirement for eligibility, however if it has been completed previously as part of the patient's health care, it should be documented for eligibility
  • Patients with treated must not have any evidence of progression on the follow-up brain imaging after central nervous system (CNS)-directed therapy.

    • Note: All treatment for brain metastases must have been completed at least 28 days prior to registration
  • Futibatinib and other therapeutic agents used in this trial are known to be teratogenic. For this reason, patients of (POCBP) and their partners with sperm-producing reproductive capacity must agree to use adequate from time of , for the duration of study participation, and for 3 months following completion of study drug therapy. Should a POCBP become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately. Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must also agree to use adequate contraception with partners of childbearing potential from time of informed consent, for the duration of study participation, and 3 months after completion of study drug administration

    • Note: A POCBP is any patient (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) with an egg-producing reproductive tract who meets the following criteria:
    • Has not undergone a hysterectomy or bilateral oophorectomy
    • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally for > 12 months)
  • POCBP must have a negative pregnancy test prior to registration on study
  • Patients must have the ability to understand and the willingness to sign a written informed consent document and comply with the study requirements
  • Patients must have the ability to swallow, retain and absorb oral medications

Exclusion criteria

Exclusion Criteria:

  • Patients with adenosquamous or mixed histology disease
  • Patients who have received/are receiving other agents, or anticancer/antineoplastic therapy including chemotherapy, immunotherapy, biological response modifiers, anti-neoplastic endocrine therapy or devices concurrently or within 21 days or 5 times the half-life, whichever is shorter, prior to first dose of cycle 1
  • Patients who have previously received a FGFR inhibitor.

    • Note: Agents that are multi-kinase inhibitors are allowed
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia, neuropathy and other non-significant adverse events per v 6.0
  • Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, ramucirumab, or futibatinib
  • Patients who have major surgical procedure planned during the study or any surgery within 28 days of registration or any subcutaneous venous access device placement within 7 days prior registration
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, or who have experienced arterial thromboembolic events, including but not limited to myocardial infarction, , cerebrovascular accident, or unstable angina, within 6 months prior to registration ,should have a clinical risk assessment of cardiac function using the Functional Classification.

    • Note: To be eligible for this trial, patients should be class 2B or better
  • History of gastrointestinal perforation and/or fistulae within 6 months prior to registration
  • History of active bleeding or significant gastrointestinal (GI) bleeding requiring intervention within 60 days prior to registration
  • History and/or current evidence of endocrine alteration of calcium-phosphorus homeostasis. History and/or current evidence of ectopic mineralization/calcification including but not limited to soft tissue, kidneys, intestine, or myocardia and lung with the exception of calcified lymph nodes and asymptomatic arterial calcification
  • Current evidence of retinal disorder/keratopathy including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, etc., confirmed by ophthalmologic examination
  • Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:

    • Hypertension that is not controlled on medication(per treating physician's discretion)
    • Ongoing or active infection requiring systemic treatment
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness/social situations that would limit compliance with study requirements
    • Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints
  • Patients with a prior or concurrent whose natural history or treatment has the potential to interfere with the safety or activity assessment of the investigational regimen (per treating physician's discretion)
  • Patients who are pregnant or nursing
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Treatment (futibatinib, paclitaxel, ramucirumab)

    Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle, and futibatinib PO QD on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI, and optional blood and urine sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Futibatinib · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel · Biological: Ramucirumab

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given PO

    Also known as: Lytgobi, TAS 120, TAS-120, TAS120

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • BiologicalRamucirumab

    Given IV

    Also known as: Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY-3009806, LY3009806, Monoclonal Antibody HGS-ETR2

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose

    Defined as the highest dose that causes dose-limiting toxicities (DLTs) in \< 2 of 6 subjects. Will be estimated using the Bayesian Optimal Interval algorithm based on observed DLTs. The frequency of DLTs at each dose level will be summarized using descriptive statistics, including proportions and confidence intervals.

    Time frame: From cycles 1 day 8 (start of Futibatinib) to cycle 2 day 8 (cycle length = 28 days)

  2. Recommended phase 2 dose

    Time frame: Up to 2 years

Secondary outcomes

  1. Incidence of adverse events

    Defined as the frequency of adverse events by type, severity (grade), timing, and attribution to \[study drugs, according the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 2 years

  2. Objective response rate

    Defined as the proportion of treated patients who experience an objective response (confirmed complete response \[CR\] or confirmed partial response \[PR\]) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be calculated with corresponding 95% confidence intervals.

    Time frame: From treatment initiation until the response has been confirmed, the patient experiences disease progression, initiates subsequent anti-cancer therapy, or completes study participation, up to 2 years after completion of study treatment

  3. Duration of response (DOR)

    Response is defined as confirmed complete response or confirmed partial response per RECIST 1.1; and disease progression is defined as progressive disease per RECIST 1.1. Will be summarized using the Kaplan-Meier method, with estimates of median DOR and corresponding 95% confidence intervals.

    Time frame: From the first scan showing CR or PR to disease progression or death, up to 2 years after completion of study treatment

  4. Progression free survival (PFS)

    PFS will be calculated based on the Kaplan-Meier estimates of PFS. Disease progression is defined as progressive disease per RECIST 1.1, other documented clinical or radiographical progression per physician judgement, or death due to disease.

    Time frame: From treatment initiation and the earlier of the day of first documented disease progression or death, up to 2 years after completion of study treatment

  5. Overall survival (OS)

    Median OS will be calculated based on the Kaplan-Meier estimates of OS.

    Time frame: From start of treatment and the date of death from any cause, up to 2 years after completion of study treatment

07

Study locations

1 of 2 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Sep 2030, 45 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2027 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 18, 2026
StartActual
Nov 10, 2026was Sep 2027
Primary completionEst.
Sep 9, 2030
CompletionEst.
Sep 9, 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Northwestern University · Chicago, United Statesno status→Recruiting
  • Ohio State University · Columbus, United Statesno status→Not yet recruiting
Nov 19, 2026
Start date
Sep 9, 2027→Nov 10, 2026 (actual)
Nov 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Northwestern University · Chicago, United StatesContact c•••@northwestern.edu · •••6180→g•••@northwestern.edu · •••9352Contact person changed (no phone or email listed)
Oct 20, 2026
Show all 2 updates
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Northwestern University · Chicago, United Statesno status→Recruiting
    • Ohio State University · Columbus, United Statesno status→Not yet recruiting
    Start date Sep 9, 2027→Nov 10, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 20, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Northwestern University · Chicago, United StatesContact c•••@northwestern.edu · •••6180→g•••@northwestern.edu · •••9352Contact person changed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07594548
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Nov 10, 2026
Primary completion
Sep 9, 2030 (estimated)
Completion
Sep 9, 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Study Coordinator
Contact
cancer@northwestern.edu
3126951301
Gladys Rodriguez, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Futibatinib · Paclitaxel · Ramucirumab

Start the discussion